Study #2018-0538
Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing A T-Cell Receptor Recognizing A Cancer/Germline Antigen As Monotherapy Or In Combination With Nivolumab In Patients With Recurrent And/Or Refractory Solid Tumors (Actengine IMA203-101)
MD Anderson Study Status
Enrolling
Treatment Agent
IMA203 Product, Nivolumab, IMA203 product- flat dose, IMA203CD8 Product
Description
The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
Study phase:
Physician name:
Dejka Araujo
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.